Systemic / IV

It delivers cells isolated from a person's own adipose tissue into the bloodstream so cells and signalling factors can reach the whole body, rather than a single injection site.

Researchers study this route in whole-body contexts such as recovery, chronic fatigue, low-grade inflammation, and vascular function.

A large body of indexed work reports potential for lower inflammatory markers, better immune balance, and support for new blood-vessel formation.

Case series and early-phase trials generally report that participants tolerate treatment well, with observed side effects that are usually mild and temporary.

Better experiences track with careful screening, standardised cell-preparation processes, and physician-led follow-up.

In many countries IV SVF is delivered within regulatory frameworks or research programmes, which raises data quality and transparency.